What is the safety profile of Sinovac for adolescents?

Question

Accepted Answer

The Sinovac Covid-19 Vaccine Demonstrates a Favourable Safety Profile for Adolescents

Extensive administration in China, involving over 63 million doses to individuals aged 12 to 17, indicates that the Sinovac Covid-19 vaccine possesses a good overall safety profile within this demographic. The Drug Control Authority (DCA) has officially approved its use for children and adolescents, with available data showing no recorded safety risks associated with its vaccination in China. The vaccine is expected to become accessible at select private healthcare facilities as an option for parents.
Extensive Real-World Data Supports Safety

Over 63 million doses of the Sinovac Covid-19 vaccine have been administered to individuals between the ages of 12 and 17 years in China. An analysis of this large-scale vaccination effort suggests a generally good safety profile for the vaccine in the child population. The majority of reported events were typical injection site reactions with mild, normal symptoms.
Regulatory Approval and Lack of Adverse Events

The Drug Control Authority (DCA) has granted approval for the Sinovac Covid-19 vaccine's use in children and adolescents. This approval follows a thorough review of its safety data. To date, there are no documented reports of safety risks or adverse events following immunisation (AEFI) linked to the vaccination of this age group in China.
Mild and Expected Side Effects

When side effects have been reported, they have typically been mild and transient. Common symptoms observed include very mild dizziness and nausea, which are considered normal reactions following vaccination. The vaccine itself is developed using inactivated virus technology, a method with over 40 years of established use in vaccine development for diseases like polio and Hepatitis A.
Availability as a Parental Option

The Sinovac Covid-19 vaccine will be made available at selected private hospitals and clinics in the near future. This will provide parents with an additional option for their children's immunisation against Covid-19, based on the established safety profile and regulatory approval. The DCA's agreement to allow the vaccine for adolescents aged 12 and above was confirmed at its 364th Meeting.

Reading history

Hide →

This history is cleared when the page is closed.

What is the safety profile of Sinovac for adolescents?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends